Actuate Therapeutics (NASDAQ:ACTU – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $15.00 price target on the stock.
Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.50.
View Our Latest Stock Report on ACTU
Actuate Therapeutics Trading Down 9.2%
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). Equities research analysts anticipate that Actuate Therapeutics will post -0.8 EPS for the current year.
Institutional Investors Weigh In On Actuate Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sfmg LLC boosted its holdings in Actuate Therapeutics by 17.6% in the fourth quarter. Sfmg LLC now owns 20,000 shares of the company’s stock worth $122,000 after purchasing an additional 3,000 shares during the last quarter. Barclays PLC boosted its holdings in Actuate Therapeutics by 68.6% in the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock worth $91,000 after purchasing an additional 6,081 shares during the last quarter. State Street Corp boosted its holdings in Actuate Therapeutics by 12.8% in the fourth quarter. State Street Corp now owns 56,290 shares of the company’s stock worth $344,000 after purchasing an additional 6,395 shares during the last quarter. ABS Direct Equity Fund LLC purchased a new stake in Actuate Therapeutics in the fourth quarter worth approximately $40,000. Finally, Wells Fargo & Company MN boosted its holdings in Actuate Therapeutics by 48.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock worth $123,000 after purchasing an additional 6,604 shares during the last quarter.
About Actuate Therapeutics
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
Read More
- Five stocks we like better than Actuate Therapeutics
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
